BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 18923170)

  • 1. Monovalent type 1 oral poliovirus vaccine in newborns.
    el-Sayed N; el-Gamal Y; Abbassy AA; Seoud I; Salama M; Kandeel A; Hossny E; Shawky A; Hussein HA; Pallansch MA; van der Avoort HG; Burton AH; Sreevatsava M; Malankar P; Wahdan MH; Sutter RW
    N Engl J Med; 2008 Oct; 359(16):1655-65. PubMed ID: 18923170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of type 1 and type 3 oral monovalent poliovirus vaccines in newborns in Africa.
    Waggie Z; Geldenhuys H; Sutter RW; Jacks M; Mulenga H; Mahomed H; De Kock M; Hanekom W; Pallansch MA; Kahn AL; Burton AH; Sreevatsava M; Hussey G
    J Infect Dis; 2012 Jan; 205(2):228-36. PubMed ID: 22158680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial of a supplemental dose of four poliovirus vaccines.
    Sutter RW; Suleiman AJ; Malankar P; Al-Khusaiby S; Mehta F; Clements GB; Pallansch MA; Robertson SE
    N Engl J Med; 2000 Sep; 343(11):767-73. PubMed ID: 10984564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monovalent type 1 oral poliovirus vaccine among infants in India: report of two randomized double-blind controlled clinical trials.
    John TJ; Jain H; Ravishankar K; Amaresh A; Verma H; Deshpande J; Pallansch MA; Singh AP; Sreevatsava M; Burton A; Malankar P; Chatterjee A; Sutter RW
    Vaccine; 2011 Aug; 29(34):5793-801. PubMed ID: 21641951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial.
    Sutter RW; John TJ; Jain H; Agarkhedkar S; Ramanan PV; Verma H; Deshpande J; Singh AP; Sreevatsava M; Malankar P; Burton A; Chatterjee A; Jafari H; Aylward RB
    Lancet; 2010 Nov; 376(9753):1682-8. PubMed ID: 20980048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fractional doses of inactivated poliovirus vaccine in Oman.
    Mohammed AJ; AlAwaidy S; Bawikar S; Kurup PJ; Elamir E; Shaban MM; Sharif SM; van der Avoort HG; Pallansch MA; Malankar P; Burton A; Sreevatsava M; Sutter RW
    N Engl J Med; 2010 Jun; 362(25):2351-9. PubMed ID: 20573923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
    O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
    Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion.
    Abbink F; Buisman AM; Doornbos G; Woldman J; Kimman TG; Conyn-van Spaendonck MA
    J Infect Dis; 2005 Mar; 191(6):990-9. PubMed ID: 15717277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India.
    Grassly NC; Jafari H; Bahl S; Durrani S; Wenger J; Sutter RW; Aylward RB
    J Infect Dis; 2009 Sep; 200(5):794-801. PubMed ID: 19624278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study.
    Van Damme P; De Coster I; Bandyopadhyay AS; Revets H; Withanage K; De Smedt P; Suykens L; Oberste MS; Weldon WC; Costa-Clemens SA; Clemens R; Modlin J; Weiner AJ; Macadam AJ; Andino R; Kew OM; Konopka-Anstadt JL; Burns CC; Konz J; Wahid R; Gast C
    Lancet; 2019 Jul; 394(10193):148-158. PubMed ID: 31174831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies.
    Mas Lago P; Ramon Bravo J; Andrus JK; Comellas MM; Galindo MA; de Quadros CA; Bell E
    Bull World Health Organ; 1994; 72(2):221-5. PubMed ID: 8205641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.
    Asturias EJ; Bandyopadhyay AS; Self S; Rivera L; Saez-Llorens X; Lopez E; Melgar M; Gaensbauer JT; Weldon WC; Oberste MS; Borate BR; Gast C; Clemens R; Orenstein W; O'Ryan G M; Jimeno J; Clemens SA; Ward J; Rüttimann R;
    Lancet; 2016 Jul; 388(10040):158-69. PubMed ID: 27212429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial.
    Estívariz CF; Jafari H; Sutter RW; John TJ; Jain V; Agarwal A; Verma H; Pallansch MA; Singh AP; Guirguis S; Awale J; Burton A; Bahl S; Chatterjee A; Aylward RB
    Lancet Infect Dis; 2012 Feb; 12(2):128-35. PubMed ID: 22071249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication.
    Cáceres VM; Sutter RW
    Clin Infect Dis; 2001 Aug; 33(4):531-41. PubMed ID: 11462191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotype-specific mucosal immune response and subsequent poliovirus replication in vaccinated children.
    Samoilovich E; Roivainen M; Titov LP; Hovi T
    J Med Virol; 2003 Oct; 71(2):274-80. PubMed ID: 12938203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early immunization of neonates with trivalent oral poliovirus vaccine.
    Weckx LY; Schmidt BJ; Herrmann AA; Miyasaki CH; Novo NF
    Bull World Health Organ; 1992; 70(1):85-91. PubMed ID: 1314711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials.
    Sáez-Llorens X; Bandyopadhyay AS; Gast C; Leon T; DeAntonio R; Jimeno J; Caballero MI; Aguirre G; Oberste MS; Weldon WC; Konopka-Anstadt JL; Modlin J; Bachtiar NS; Fix A; Konz J; Clemens R; Costa Clemens SA; Rüttimann R
    Lancet; 2021 Jan; 397(10268):27-38. PubMed ID: 33308427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine.
    Ciarlet M; Sani-Grosso R; Yuan G; Liu GF; Heaton PM; Gottesdiener KM; Arredondo JL; Schödel F
    Pediatr Infect Dis J; 2008 Oct; 27(10):874-80. PubMed ID: 18756184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of oral poliovirus vaccine administered in mass campaigns versus routine immunization programmes.
    Richardson G; Linkins RW; Eames MA; Wood DJ; Campbell PJ; Ankers E; Deniel M; Kabbaj A; Magrath DI; Minor PD
    Bull World Health Organ; 1995; 73(6):769-77. PubMed ID: 8907770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.